Tag: Corporate

Hong Kong, July 11, 2025 (GLOBE NEWSWIRE) -- Happy City Holdings Limited (Nasdaq: HCHL) (the “Company”), an established all-you-can-eat hotpot restaurant operator in Hong Kong, today announced that the underwriters of its previously announced initial public offering (the “Offering”) have partially exercised their over-allotment option (the “Over-Allotment Option”) to purchase an additional 112,000 Class A Ordinary Shares at the public offering price of $5.00 per share, resulting in additional gross proceeds of $0.56 million. After giving effect to the partial exercise of the Over-Allotment Option, the total number of Class A Ordinary Shares sold by the Company in the Offering increased to 1,212,000 shares and the gross proceeds increased to $6.06 million, before deducting underwriting discounts and other related expenses. The Over-Allotment Option closing date was July 11, 2025. The Class A Ordinary Shares began trading on the Nasdaq Capital Market June 24, 2025 under the symbol “HCHL.”

Award Recognition underscores the importance of AI-driven drug discovery

MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone^® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of (i) 31,500,000 of its common shares (the “Shares”), accompanying Series A common warrants (the “Series A Common Warrants”) to purchase an aggregate of 31,500,000 common shares and accompanying Series B common warrants (the “Series B Common Warrants”) to purchase an aggregate of 31,500,000 common shares , at a combined public offering price of $1.50 per share and accompanying Series A Common Warrant and Series B Common Warrant and (ii) in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase 3,502,335 common shares, accompanying Series A Common Warrants to purchase an aggregate of 3,502,335 common shares and accompanying Series B Common Warrants to purchase an aggregate of 3,502,335 common shares, at a combined public offering price of $1.499 per pre-funded warrant and accompanying Series A Common Warrant and Series B Common Warrant, which represents the combined public offering price for the Shares and accompanying common warrants less the $0.001 per share exercise price for each such pre-funded warrant. The proceeds to Milestone from the Offering, before deducting underwriting commissions and offering expenses payable by Milestone, are expected to be approximately $52.5 million. The Offering is expected to close on or about July 14, 2025, subject to satisfaction of customary closing conditions.

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

New additions bolster Hapbee as it scales product reach, tech pipeline, and international presence.

SOUTH SAN FRANCISCO, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 2,100 shares of the Company’s stock (the “Inducement Grant”) to newly hired employees on July 8, 2025 (the “Grant Date”), in connection with the commencement of employment.